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Abstract
Alzheimer’s disease is a progressive incurable neurodegenerative disease manifested by dementia and other cognitive
disorders. Gene-cell therapy is one of the most promising trends in the development of treatment for Alzheimer’s disease.
The study was aimed to evaluate the therapeutic potential of intravenous transplantation of human umbilical cord blood
mononuclear cells (UCBMCs) transduced with adenoviral vectors overexpressing nerve growth factor (NGF) for the
treatment of Alzheimer’s disease in an APP/PS1 transgenic mice model. The transplantation of NGF-expressing
UCBMCs was found to improve spatial memory and decrease anxiety in APP/PS1 mice. Grafted cells and their expression
of NGF were detected in the cortex and hippocampus of transgenic mice in the period up to 90 days after transplantation.
Thus, gene-cell therapy based on the use of NGF-overexpressing UCBMCs is a promising approach for the development
of Alzheimer’s disease treatments.
Keywords Alzheimer’s disease .Nerve growth factor . Stemcells .Gene-cell therapy .APP/PS1 transgenicmice .Umbilical cord
bloodmononuclear cells
1 Introduction
Alzheimer’s disease is a progressive incurable neurodegenerative
disease manifested by dementia and other cognitive disorders.
Excessive production and accumulation of neurotoxic β-
amyloid peptide in nervous and other tissues is thought by most
of researchers to be a key factor in Alzheimer’s disease pathogen-
esis [1–3]. To date, the considerable experience in the search and
use of various drugs for treatment of Alzheimer’s disease is ob-
tained; however, there is still no effective cure available. Thus, the
development of novel therapeutic approaches to treat Alzheimer’s
disease is one of the most important goals for medical science.
The use of umbilical cord blood mononuclear cells
(UCBMCs) to deliver various neurotrophic factors into the
sites of neurodegeneration is a promising approach in the de-
velopment of therapy for neurodegenerative diseases [4–8]. A
nerve growth factor (NGF), a protein of the family of
neurotrophins which is involved in the maintenance of surviv-
al, stimulation of growth, and activity of neurons, has a sig-
nificant therapeutic potential in this regard [9, 10]. NGF was
shown to prevent neuronal death in a number of models of
neurodegenerative disorders [11–14]. NGF has a positive ef-
fect on neuronal survival, synaptic function, and memory in
models of Alzheimer’s disease [7]. A recombinant NGF gene
can be delivered into sites of neurodegeneration using gene-
cell constructs.
This study is aimed to transplant UCBMCs transduced
with adenoviral vectors expressing NGF to transgenic mice
with a model of Alzheimer’s disease (APP/PS1 line) with
subsequent evaluation of mice behavior and the ability of
grafted cells for homing, survival, and expression of a thera-
peutic gene in the brain.
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